| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
010-82848833 400-666-7788 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:1-[[3-Fluoro-4-[5-[(2-fluorophenyl)Methyl]-2-benzothiazolyl]phenyl]Methyl]-3-azetidinecarboxylic Acid
CAS:1257093-40-5
Package:100Mg,10Mg,50Mg
|
| Company Name: |
Shanghai TaoSu Biochemical Technology Co., Ltd.
|
| Tel: |
021-33632979 |
| Email: |
info@tsbiochem.com |
| Products Intro: |
Product Name:1-[[3-Fluoro-4-[5-[(2-fluorophenyl)Methyl]-2-benzothiazolyl]phenyl]Methyl]-3-azetidinecarboxylic Acid
CAS:1257093-40-5
Purity:90% Package:10Mg;50Mg;100Mg;
|
| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:TC-SP 14
CAS:1257093-40-5
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
TC-SP 14 manufacturers
- TC-SP 14
-
- $1980.00 / 50mg
-
2024-10-28
- CAS:1257093-40-5
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | TC-SP 14 Basic information |
| | TC-SP 14 Chemical Properties |
| Boiling point | 608.1±65.0 °C(Predicted) | | density | 1.396±0.06 g/cm3(Predicted) | | storage temp. | Desiccate at RT | | solubility | <22.52mg/ml in DMSO | | form | solid | | pka | 2.65±0.20(Predicted) | | color | Off-white |
| | TC-SP 14 Usage And Synthesis |
| Uses | 1-[[3-Fluoro-4-[5-[(2-fluorophenyl)methyl]-2-benzothiazolyl]phenyl]methyl]-3-azetidinecarboxylic Acid is a potent Sphingosine-1-Phosphate Receptor 1 (S1P1) agonist with minimal activity at S1P3. It has been shown to attenuate DTH response to antigen challenge while significantly reducing blood lymphocyte counts. | | Biological Activity | ec50: 0.042 μm for hs1p1tc-sp 14 is an agonist of sphingosine-1-phosphate receptor 1 (s1p1).studies have revealed that the lysophospholipid sphingosine-1-phosphate (s1p1) is a pleiotropic modulator of diverse cellular processes. such effects are reported to be mediated by the interactions of s1p with a set of paralogous g proteincoupled receptors, which are widely expressed in the immune, central nervous and cardiovascular systems. | | in vitro | as a small lipophilic substituent proved equally effective to a larger substituent in reducing s1p3 activity, tc-sp 14 was screened. tc-sp 14 was found to be a potent s1p1 agonist (ec50 = 0.042 μm) with reduced activity for s1p3 (ec50 = 3.47 μm) [1]. | | in vivo | in lewis rats, tc-sp 14 produced a dose-dependent reduction in circulating blood lymphocytes, which was consistent with s1p1 agonism. moreover, statistical significance was shown at a dose of 0.3 mg/kg, and the dose fo 3.0 mg/kg led to near maximal lymphopenia. tc-sp 14 was subsequently investigated in a dth antigen challenge model. results showed a statistically significant reduction in ear swelling at doses of 0.3 mg/kg and higher. in addition, reduced ear swelling was found to closely track circulating lymphocyte counts [1]. | | references | [1] lanman ba,cee vj,cheruku sr et al. discovery of a potent, s1p3-sparing benzothiazole agonist of sphingosine-1-phosphate receptor 1 (s1p1). acs med chem lett.2010 nov 9;2(2):102-6. |
| | TC-SP 14 Preparation Products And Raw materials |
|